ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Hederagenin Attenuates Morphine Addiction via GABAA1-Mediated Modulation of Ca
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Morphine-associated contextual reward learning promotes maladaptive drug-context associations during opioid exposure. Hederagenin (HE), a bioactive compound from traditional Chinese medicine, has neuroprotective potential, but its role in contextual reward learning remains unclear. Here, we investigated the effects of HE on morphine-induced conditioned place preference (CPP) acquisition and explored its target, downstream signaling, and brain-delivery strategy. HE attenuated morphine CPP acquisition in both sexes and reduced established CPP expression. Chemical proteomics identified the GABAA receptor α1 subunit (GABAA1, encoded by GABRA1) as a prioritized HE-associated target, supported by competitive pull-down, non-permeabilized HE-biotin labeling, microscale thermophoresis, cellular thermal shift assay, and molecular docking. Mechanistically, HE reduced c-Fos activation in ventral tegmental area (VTA) TH-positive dopaminergic neurons, attenuated reward-context-associated VTA calcium responses, suppressed intracellular Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.